Buyer question this answers
How do we avoid funding generic automation while still moving quickly on high-pain manufacturing workflows?
Why this roadmap is credible
- It starts from observed pain and available records, not abstract ideation.
- It makes sequencing explicit: instrument first where evidence is weak.
- It protects strategic bets by showing why they are different from commodity automation.
What to copy into your own assessment
- Quantify one recurring operational pain.
- Link that pain to process owners and accessible evidence.
- Promote missing evidence to named prerequisite work.